CSI Market
Sign In | Register

Corcept Therapeutics Inc (CORT) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access CORT Annual Income Statement →
The data below summarizes Corcept Therapeutics Inc's income statement results from Sep 30 2025 to Sep 30 2026, enabling period-by-period comparison of operating performance.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CORT/income-statements
https://api.csimarket.com/api/v1/companies/CORT/fundamentals
https://api.csimarket.com/api/v1/companies/CORT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2026)
Q3 2026 		(Jun 30 2026) (Mar 31 2026) (Dec 31 2025) (Sep 30 2025)
Revenues
Revenue From Contract With Customer Excluding Assessed Tax340.47
Total Revenue340.47
Costs & Expenses
Cost of Goods and Services Sold4.61
Gross Profit335.86
Selling, Administration, Marketing164.43
Depreciation & Amortization0.00
Research and Development Expense56.71
Other Operating Expense / -Income0.00
Total operating costs including COS225.75
Operating income / -loss114.72
Net Interest (-)Expense / Income0.00
Loss / -Gain on Investment-1.94
Other loss / -income0.00
Total costs & expenses225.75
Income & Taxes
Income / -loss before income taxes120.31
Income taxes expenses / -benefit-6.47
Income after income taxes126.78
Net income / -loss of other equity0.00
Income / -loss from continuing operations126.78
Net income / -loss126.78
Income / -loss to shareholder124.49
EBIT120.31
EBITD121.33
EBITDA121.33
Earnings Per Share
Basic EPS (excl. extra items)1.17
Basic Net EPS1.17
Basic shares outstanding (Mill. of Units)106.63
Diluted Net EPS1.01
Diluted average shares (Mill. of Units)123.20
4 historic quarters locked

Sign in to unlock the full Corcept Therapeutics Inc income statement history.

Sign In Create Free Account

About Corcept Therapeutics Inc Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: November 3, 2026
  • Original filing: cort-20260930.htm

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API Connect Your AI